AltrixBio Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $11.6M

  • Investors
  • 9

AltrixBio General Information

Description

Developer of therapeutic drugs designed for controlled gastrointestinal targeting. The company's drugs treat patients with obesity by providing duodenal isolation similar to gastric bypass, restricting the absorption of fats and glucose through the mucosa in the bowels, helping to reduce glucose levels, enabling patients with an oral medication that replicates the metabolic success of bariatric surgery and is more financially feasible than surgery.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 325 Vassar Street
  • Suite 2A
  • Cambridge, MA 02139
  • United States
+1 (302)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 325 Vassar Street
  • Suite 2A
  • Cambridge, MA 02139
  • United States
+1 (302)

AltrixBio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AltrixBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series A) 16-Sep-2025 $11.6M Completed Generating Revenue
4. Early Stage VC 01-Nov-2023 Completed Pre-Clinical Trials
3. Early Stage VC 01-Jan-2022 Completed Pre-Clinical Trials
2. Seed Round 04-Jun-2020 $3.2M $3.3M Completed Pre-Clinical Trials
1. Seed Round 01-Nov-2019 $100K $100K Completed Pre-Clinical Trials
To view AltrixBio’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

AltrixBio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of therapeutic drugs designed for controlled gastrointestinal targeting. The company's drugs treat patients wi
Drug Discovery
Cambridge, MA
7 As of 2026

Baltimore, MD
 

Burlington, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AltrixBio Competitors (4)

One of AltrixBio’s 4 competitors is Glyscend Therapeutics, a Venture Capital-Backed company based in Baltimore, MD.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Glyscend Therapeutics Venture Capital-Backed Baltimore, MD
Fractyl Health Formerly VC-backed Burlington, MA
Morphic Medical Private Equity-Backed Boston, MA
GI Windows Venture Capital-Backed Canton, MA
To view AltrixBio’s complete competitors history, request access »

AltrixBio Patents

AltrixBio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230310314-A1 Mucoadhesive compositions for directional delivery of active agents Inactive 28-Feb-2022
WO-2023164706-A1 Mucoadhesive compositions for directional delivery of active agents Inactive 28-Feb-2022

AltrixBio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AltrixBio Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
StageNext Fund Venture Capital Minority
Service Provider Capital Venture Capital Minority
100 Plus Capital Impact Investing Minority
Arizona Tech Investors Angel Group Minority
Flybridge (New York) Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

AltrixBio FAQs

  • When was AltrixBio founded?

    AltrixBio was founded in 2019.

  • Where is AltrixBio headquartered?

    AltrixBio is headquartered in Cambridge, MA.

  • What is the size of AltrixBio?

    AltrixBio has 7 total employees.

  • What industry is AltrixBio in?

    AltrixBio’s primary industry is Drug Discovery.

  • Is AltrixBio a private or public company?

    AltrixBio is a Private company.

  • What is AltrixBio’s current revenue?

    The current revenue for AltrixBio is .

  • How much funding has AltrixBio raised over time?

    AltrixBio has raised $14.9M.

  • Who are AltrixBio’s investors?

    StageNext Fund, Service Provider Capital, 100 Plus Capital, Arizona Tech Investors, and Flybridge (New York) are 5 of 9 investors who have invested in AltrixBio.

  • Who are AltrixBio’s competitors?

    Glyscend Therapeutics, Fractyl Health, Morphic Medical, and GI Windows are competitors of AltrixBio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process